Marker Therapeutics, Inc. (MRKR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Marker Therapeutics, Inc. (MRKR) Healthcare & Pipeline Overview

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing MultiTAA-specific T cell therapies and peptide-based vaccines for hematological malignancies and solid tumors. Their innovative approach targets multiple tumor-associated antigens, positioning them within the competitive biotechnology landscape focused on novel cancer treatments.

What Is the Investment Thesis for MRKR?

Marker Therapeutics' investment thesis centers on its MultiTAA-specific T cell technology and its potential to deliver effective cancer treatments. The company's diverse pipeline, including autologous, allogeneic, and off-the-shelf T cell therapies, provides multiple avenues for growth. Key value drivers include the successful completion of clinical trials for TPIV200 (Phase 2) and the advancement of its MultiTAA-specific T cell therapies. The company's ability to secure partnerships and funding will be crucial for advancing its clinical programs. A potential risk factor is the high attrition rate in clinical-stage biotechnology companies, particularly in oncology. Achieving positive clinical outcomes and navigating regulatory pathways are critical for realizing the company's potential. The company's market capitalization is approximately $0.02 billion as of May 9, 2026.

Based on FMP financials and quantitative analysis

MRKR Key Highlights

Market capitalization of $20.0M reflects the company's current valuation in the biotechnology market.

• Gross margin of -137.3% indicates significant investment in research and development relative to revenue.
• Profit margin of -343.0% highlights the company's focus on clinical development and limited commercial product revenue.
• Beta of 1.47 suggests higher volatility compared to the overall market, typical for clinical-stage biotech companies.
• Focus on MultiTAA-specific T cell technology provides a differentiated approach to cancer immunotherapy.

Who Are MRKR's Competitors?

MRKR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MRKR's Key Strengths?

Proprietary MultiTAA-specific T cell technology.

• Diverse pipeline of autologous, allogeneic, and off-the-shelf T cell therapies.
• Focus on multiple tumor-associated antigens for enhanced efficacy.
• Phase 2 clinical trial for TPIV200.

What Are MRKR's Weaknesses?

Limited financial resources as a clinical-stage company.

• Negative gross and profit margins.
• Small number of employees.
• Dependence on clinical trial outcomes.

What Could Drive MRKR Stock Higher?

Announcement of Phase 2 clinical trial results for TPIV200 in breast and ovarian cancers.

• Enrollment and progress in clinical trials for MultiTAA-specific T cell therapies.
• Potential for strategic partnerships and collaborations with pharmaceutical companies.
• Regulatory submissions and potential approvals for its therapies.

What Are the Key Risks for MRKR?

Financial-distress signal — its Altman Z-Score of -40.44 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-73.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays.
• Regulatory hurdles and delays in obtaining approvals.
• Competition from established pharmaceutical companies and other biotechnology firms.
• Financial constraints and the need for additional funding.
• Manufacturing challenges and scalability issues for cell therapies.

What Are the Growth Opportunities for MRKR?

• Expansion of Clinical Trials: Marker Therapeutics has the opportunity to expand its clinical trials for TPIV200 and its MultiTAA-specific T cell therapies. Positive results from these trials could lead to accelerated regulatory approval and commercialization. The market for breast and ovarian cancer treatments is substantial, with projections indicating continued growth. Successfully navigating Phase 3 trials and demonstrating efficacy could significantly increase the company's market value and attract partnerships.
• Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions can provide Marker Therapeutics with access to additional funding, expertise, and resources. Collaborations can accelerate the development and commercialization of its therapies. The biotechnology industry is characterized by collaborations, and successful partnerships can enhance the company's credibility and market reach. Securing such partnerships is crucial for long-term growth and sustainability.
• Advancement of Off-the-Shelf T Cell Therapies: Developing off-the-shelf T cell therapies represents a significant growth opportunity for Marker Therapeutics. These therapies offer the potential for broader accessibility and faster treatment compared to autologous cell therapies. The market for allogeneic cell therapies is expanding, driven by the demand for scalable and cost-effective treatments. Successful development and commercialization of off-the-shelf products could position the company as a leader in the cell therapy space.
• Expansion into New Therapeutic Areas: Marker Therapeutics can expand its focus to new therapeutic areas beyond hematological malignancies and breast/ovarian cancers. Exploring the potential of its MultiTAA-specific T cell technology in other solid tumors or autoimmune diseases could broaden its market reach and diversify its pipeline. The immuno-oncology field is continuously evolving, and identifying new applications for its technology can drive long-term growth.
• Securing Regulatory Approvals: Obtaining regulatory approvals from the FDA and other regulatory agencies is critical for commercializing Marker Therapeutics' therapies. Successful navigation of the regulatory process and demonstration of clinical efficacy and safety are essential for market access. The regulatory landscape for cell therapies and vaccines is complex, and securing approvals requires robust clinical data and a well-defined regulatory strategy. Achieving these milestones will unlock significant value for the company.

What Are MRKR's Competitive Advantages?

• Proprietary MultiTAA-specific T cell technology.
• Patent protection for its immunotherapies and vaccines.
• Clinical data demonstrating efficacy and safety.
• Expertise in cell therapy development and manufacturing.

What Does MRKR Do?

Founded in 1999 and headquartered in Houston, Texas, Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company dedicated to developing and commercializing T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company's core technology, MultiTAA-specific T cell therapy, leverages non-engineered tumor-specific T cells that recognize and kill tumor cells expressing multiple tumor-associated antigens. This approach aims to provide a more robust and targeted immune response compared to therapies targeting single antigens. Marker Therapeutics' pipeline includes autologous T cell therapies for lymphoma and various solid tumors, allogeneic T cell therapies for acute myeloid leukemia and acute lymphoblastic leukemia, and off-the-shelf products for various indications. Furthermore, the company is developing peptide-based immunotherapeutic vaccines, including TPIV100/110 for breast and ovarian cancer cells and TPIV200, which is currently in Phase 2 clinical trials for the treatment of breast and ovarian cancers. These therapies represent a diverse approach to cancer treatment, addressing both hematological and solid tumor malignancies. The company's focus on innovative immunotherapies positions it within the rapidly evolving biotechnology sector, aiming to provide effective and personalized cancer treatments.

What Products and Services Does MRKR Offer?

• Develops T cell-based immunotherapies for cancer treatment.
• Creates peptide-based vaccines for hematological malignancies and solid tumors.
• Utilizes MultiTAA-specific T cell technology to target multiple tumor-associated antigens.
• Focuses on autologous T cell therapies for lymphoma and solid tumors.
• Develops allogeneic T cell therapies for acute myeloid leukemia and acute lymphoblastic leukemia.
• Advances off-the-shelf T cell products for various cancer indications.
• Conducts Phase 2 clinical trials for TPIV200 in breast and ovarian cancers.

How Does MRKR Make Money?

• Develops and patents novel immunotherapies and vaccines.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approvals for commercialization.
• Potentially partners with larger pharmaceutical companies for manufacturing and distribution.

What Industry Does MRKR Operate In?

Marker Therapeutics operates within the competitive biotechnology industry, which is characterized by rapid innovation and high-risk, high-reward opportunities. The immuno-oncology segment, in particular, has seen significant growth, driven by the success of checkpoint inhibitors and CAR-T cell therapies. Marker Therapeutics' MultiTAA-specific T cell technology positions it within this innovative space, competing with companies developing similar cell-based therapies and peptide vaccines. The industry is driven by the increasing prevalence of cancer and the demand for more effective and personalized treatments.

Who Are MRKR's Key Customers?

• Hospitals and cancer treatment centers.
• Oncologists and hematologists.
• Patients with hematological malignancies and solid tumors.
• Potential pharmaceutical partners for licensing and collaboration.

The most recent 11 insider filings for Marker Therapeutics, Inc. break down as 0 sales and 11 purchases. On net that is roughly 1.2M shares acquired (about $1.2M) — insiders putting money in tends to read as conviction.

Marker Therapeutics, Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 22.6% above estimates on average.

Marker Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -40.44 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Marker Therapeutics, Inc. stands at -73.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -62.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -49.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.79 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -38.1%, the inverse of the P/E and a quick read on earnings relative to price.

Marker Therapeutics, Inc. (MRKR) Valuation Context

Valued at $20.0M, MRKR is classified as a micro-cap stock. Relative to its peer group, MRKR's quantitative score of 18/100 is below the peer average of 75/100.

MRKR Revenue & Earnings Trend

In Q2 FY2026, MRKR generated $0 in top-line revenue. The company recorded a net loss of $1.8M, with diluted EPS of $-0.09. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, MRKR averaged $-0.12 in diluted EPS.

Company Profile

Marker Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Houston, US. The company is led by CEO Juan F. Vera. MRKR has traded publicly since 2002.

MRKR Financials

MRKR Latest News

MRKR Analyst Consensus

MRKR MoonshotScore

Common Questions About MRKR (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources